Cordycepin - Daoboqin Pharmaceutical Technology
Latest Information Update: 28 May 2026
At a glance
- Originator Daoboqin Pharmaceutical Technology
- Class Amines; Antifungals; Antineoplastics; Nucleosides; Purines; Small molecules
- Mechanism of Action DNA methylation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Gastric cancer
Most Recent Events
- 28 May 2026 No recent reports of development identified for preclinical development in Colorectal-cancer(Combination therapy) in China (PO)
- 28 May 2026 No recent reports of development identified for preclinical development in Gastric-cancer(Combination therapy) in China (PO)
- 08 Apr 2022 Preclinical trials in Colorectal cancer (Combination therapy) in China (PO), before April 2022